A 48-year-old woman with newly diagnosed type 2 diabetes mellitus (fasting glucose 160 mg/dL, HbA1c 8.5%) and chronic kidney disease stage 3b (eGFR 38 mL/min/1.73m²) presents for management. She has no history of cardiovascular disease. Which of the following oral hypoglycemic agents should be avoided in this patient?

Explanation

## Clinical Context This patient has newly diagnosed type 2 diabetes with moderate-to-advanced chronic kidney disease (CKD stage 3b, eGFR 38 mL/min/1.73m²). The question tests knowledge of which agents are contraindicated or require dose adjustment in renal impairment. ## Renal Function and Oral Hypoglycemic Safety | Agent | Class | eGFR Threshold for Caution | eGFR Threshold for Contraindication | Status in This Patient (eGFR 38) | |-------|-------|----------------------------|-------------------------------------|----------------------------------| | Metformin | Biguanide | <45 mL/min/1.73m² | <30 mL/min/1.73m² | **AVOID** — risk of lactic acidosis | | Empagliflozin | SGLT-2 inhibitor | No absolute contraindication | Safe down to eGFR 20 | **SAFE** — renoprotective | | Linagliptin | DPP-4 inhibitor | No dose adjustment needed | Safe in all stages of CKD | **SAFE** — hepatic metabolism | | Saxagliptin | DPP-4 inhibitor | eGFR <45: reduce dose | eGFR <30: further caution | **CAUTION** — requires dose reduction | ## Key Point: **Metformin should be avoided** in this patient because: 1. eGFR of 38 mL/min/1.73m² is in the range where metformin accumulation increases the risk of **lactic acidosis** 2. Current guidelines recommend avoiding metformin when eGFR <45 mL/min/1.73m² 3. Metformin is renally cleared and accumulates in renal impairment 4. The risk-benefit ratio is unfavorable when safer alternatives exist ## High-Yield: **Metformin dosing in CKD:** - eGFR ≥45: No dose adjustment - eGFR 30–44: Use with caution, maximum 1000 mg/day, monitor renal function - eGFR <30: **Contraindicated** [cite:KD Tripathi 8e Ch 48] ## Mnemonic: **"SGLT-2 and DPP-4 are safe in CKD; metformin is not"** - **S**SGLT-2 inhibitors: Renoprotective, safe in CKD - **D**DP-4 inhibitors: Hepatically metabolized, safe in CKD (except saxagliptin requires dose reduction) - **M**etformin: Renally cleared, accumulates in CKD ## Clinical Pearl: In CKD stage 3b with newly diagnosed diabetes, **SGLT-2 inhibitors (empagliflozin, dapagliflozin) are preferred** because they provide: - Glycemic control - Renoprotection (reduce proteinuria, slow GFR decline) - Cardiovascular protection - No hypoglycemia risk